Peak Capital Management’s GSK GSK Stock Holding History

Peak Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-183	Closed	-$9K	–	104
2018 Q2	$9K	Buy	+183	New	+$9.22K	0.01%	135

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Peak Capital Management's GSK Position: Q3 2018 in Review

Peak Capital Management sold out of GSK (GSK) in Q3 2018, closing a stake of 183 shares — an estimated $9K sold.

Peak Capital Management first reported a position in GSK in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 787 funds tracked by Wall St. Rank hold GSK as of Q3 2018.

Peak Capital Management reported no remaining GSK position as of Q3 2018 after selling out during the quarter.
Peak Capital Management sold 183 GSK shares in Q3 2018, an estimated $9K.
Peak Capital Management first reported a position in GSK in Q2 2018 and held it in 1 quarter.
Peak Capital Management's GSK position peaked at $9K in Q2 2018.
787 funds tracked by Wall St. Rank held GSK as of Q3 2018.

Based on Peak Capital Management's 13F filing for Q3 2018, filed 20 Nov 2018.